Equity Overview
Price & Market Data
Price: $1.45
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $104,596,488
Daily Volume: 0
Performance Metrics
1 Week: 5.07%
1 Month: 10.69%
3 Months: 17.89%
6 Months: -32.24%
1 Year: -57.73%
YTD: -52.15%
Company Details
Employees: 166
Sector: Health technology
Industry: Biotechnology
Country:
Details
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.